The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Walking the tightrope between ischaemia and bleeding

EuroIntervention 2021;17:527-529. DOI: 10.4244/EIJV17I7A93

1. TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA, USA
Ischaemic events and bleeding remain common complications in patients with coronary artery disease (CAD), particularly after an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI). While intensification and prolongation of antiplatelet therapies help to attenuate the risk of thrombotic events, this benefit is typically accompanied by a significant increase in major and minor bleeding. To date, several studies have highlighted that bleeding is associated with an increased risk of death1. However, the relative prognostic impact of a bleeding event versus myocardial infarction (MI) remains disputed. Some trials of more intensive antithrombotic therapy have demonstrated a reduction in both recurrent ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Coronary sinus reducer therapy for refractory angina: is it ready for prime time?